title: Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.
abstract: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin Lymphoma (HL) include the clinical management of classical HL and lymphocyte-predominant HL (LPHL). Major changes have been incorporated into these guidelines since their inception. In the 2012 NCCN Guidelines for HL, PET scans are not recommended for interim restaging of patients with stage I to II favorable disease. After reevaluating the available evidence on the use of interim PET imaging, the panel recommends the use of diagnostic CT scan of involved sites for interim restaging after completion of chemotherapy for this group of patients. Maintenance rituximab for 2 years is included as an option for patients with stage IB to IIB or stage III to IV LPHL treated with rituximab alone in the first-line setting. Brentuximab vedotin is included as an option for patients with progressive disease or relapsed disease after second-line chemotherapy or high-dose therapy with autologous stem cell rescue.
authors.affiliation: Stanford Cancer Institute.
authors.forename: Richard T
authors.initials: RT
authors.lastname: Hoppe
authors.forename: Ranjana H
authors.initials: RH
authors.lastname: Advani
authors.forename: Weiyun Z
authors.initials: WZ
authors.lastname: Ai
authors.forename: Richard F
authors.initials: RF
authors.lastname: Ambinder
authors.forename: Patricia
authors.initials: P
authors.lastname: Aoun
authors.forename: Celeste M
authors.initials: CM
authors.lastname: Bello
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Bierman
authors.forename: Kristie A
authors.initials: KA
authors.lastname: Blum
authors.forename: Robert
authors.initials: R
authors.lastname: Chen
authors.forename: Bouthaina
authors.initials: B
authors.lastname: Dabaja
authors.forename: Ysabel
authors.initials: Y
authors.lastname: Duron
authors.forename: Andres
authors.initials: A
authors.lastname: Forero
authors.forename: Leo I
authors.initials: LI
authors.lastname: Gordon
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Hernandez-Ilizaliturri
authors.forename: Ephraim P
authors.initials: EP
authors.lastname: Hochberg
authors.forename: David G
authors.initials: DG
authors.lastname: Maloney
authors.forename: David
authors.initials: D
authors.lastname: Mansur
authors.forename: Peter M
authors.initials: PM
authors.lastname: Mauch
authors.forename: Monika
authors.initials: M
authors.lastname: Metzger
authors.forename: Joseph O
authors.initials: JO
authors.lastname: Moore
authors.forename: David
authors.initials: D
authors.lastname: Morgan
authors.forename: Craig H
authors.initials: CH
authors.lastname: Moskowitz
authors.forename: Matthew
authors.initials: M
authors.lastname: Poppe
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
authors.forename: Jane N
authors.initials: JN
authors.lastname: Winter
authors.forename: Joachim
authors.initials: J
authors.lastname: Yahalom
authors.forename: Hema
authors.initials: H
authors.lastname: Sundar
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008495:Medical Oncology / Q000592:standards*; D009367:Neoplasm Staging / Q000379:methods; D049268:Positron-Emission Tomography / Q000379:methods
chemical_list: D000970:Antineoplastic Agents